Ignet

Gene Information

Gene symbol: IL17F

Gene name: interleukin 17F

HGNC ID: 16404

Synonyms: IL-17F, ML-1, ML1

Related Genes

#	Gene Symbol	Number of hits
1	CD59	1 hits
2	GPSM3	1 hits
3	IFNG	1 hits
4	IGF1	1 hits
5	IL12A	1 hits
6	IL17A	1 hits
7	IL17C	1 hits
8	IL17D	1 hits
9	IL22	1 hits
10	IL23A	1 hits
11	IL6	1 hits
12	INS	1 hits
13	MUC5B	1 hits
14	REN	1 hits
15	TGFB1	1 hits
16	UMOD	1 hits

Related Sentences

#	PMID	Sentence
1	1794265	In healthy subjects, the glucose load after placebo induced an insulin response of 7.4 +/- 1.0 and 11.3 +/- 1.4 microU ml-1 min-1 mg-1 dl-1 for the first and second phases, respectively, and an insulin sensitivity evaluated to be 4.7 +/- 0.3 min microU-1 ml-1.
2	1794265	In diabetic subjects the insulin response to the glucose load after placebo was markedly decreased (2.2 +/- 0.5 and 2.5 +/- 0.3 microU ml-1 min-1 mg-1 dl-1, respectively) as was the insulin sensitivity (2.5 +/- 0.3 min microU-1 ml-1).
3	1794265	In healthy subjects, the glucose load after placebo induced an insulin response of 7.4 +/- 1.0 and 11.3 +/- 1.4 microU ml-1 min-1 mg-1 dl-1 for the first and second phases, respectively, and an insulin sensitivity evaluated to be 4.7 +/- 0.3 min microU-1 ml-1.
4	1794265	In diabetic subjects the insulin response to the glucose load after placebo was markedly decreased (2.2 +/- 0.5 and 2.5 +/- 0.3 microU ml-1 min-1 mg-1 dl-1, respectively) as was the insulin sensitivity (2.5 +/- 0.3 min microU-1 ml-1).
5	2850132	Acute and long-term renal effects of angiotensin converting enzyme inhibition in normotensive, normoalbuminuric insulin-dependent diabetic patients.
6	2850132	Glomerular filtration rate (GFR) (thalamate clearance), renal plasma flow (RPF) (hippuran clearance), and urinary albumin excretion rate (AER) were measured in 10 normoalbuminuric, normotensive insulin-dependent diabetic patients and 8 normal subjects before and during acute angiotensin converting enzyme (ACE) inhibition by means of enalapril (10 mg IV).
7	2850132	The decline in total renal resistance was not significant (0.175 +/- 0.013 to 0.165 +/- 0.012 mmHg ml-1 min-1) and significant changes in GFR, RPF, mean arterial pressure or HbA1c were not observed.
8	3130265	Adhesion of bacteria (without additions: 100 bacteria per cell) was reduced dose-dependently by THP, half maximal inhibition occurring with 250 micrograms THP ml-1.
9	3130265	Maximal inhibition (-84% at 1000 micrograms ml-1) exceeded inhibition by alpha-methyl-mannoside (36% at 50 mM), was specific (not reproduced by other glycoproteins, e.g. ovalbumin, mucin or thyroglobulin) and reversible (abolished by washing THP off HUK cells).
10	3130265	Anti-adherence property of THP was not abolished by neuraminidase treatment.
11	3516773	Respective basal and post-stimulated (with intravenous furosemide 40 mg plus 60 min ambulation) plasma aldosterone concentrations measured in control subjects and in hypertensive diabetic patients with nephropathy were similar and increased to the same extent in the 2 groups (5.5 +/- 3.2 versus 5.3 +/- 3.2 and 9.3 +/- 2.6 versus 10.5 +/- 3.4 ng/ml), although the respective plasma renin activity tended to be lower in diabetic patients than in control subjects (0.7 +/- 0.6 versus 1.3 +/- 0.9 and 1.8 +/- 1.8 versus 3.0 +/- 2.6 ng-1 . ml-1 . h-1).
12	7788231	Values for perfusion in eight normal pancreases ranged between 1.25 and 1.66 ml min-1 ml-1 (mean: 1.52 ml min-1 ml-1).
13	7788231	Increased perfusion values were present in a patient with an islet cell tumour (overall perfusion 2.11 ml min-1 ml-1) and a patient with Wilson's disease (3.43 ml min-1 ml-1).
14	7788231	Pancreatic perfusion was reduced in a patient with diabetes (0.60 ml min-1 ml-1) and in a failing pancreatic transplant (0.97 ml min-1 ml-1).
15	7788231	Values for perfusion in eight normal pancreases ranged between 1.25 and 1.66 ml min-1 ml-1 (mean: 1.52 ml min-1 ml-1).
16	7788231	Increased perfusion values were present in a patient with an islet cell tumour (overall perfusion 2.11 ml min-1 ml-1) and a patient with Wilson's disease (3.43 ml min-1 ml-1).
17	7788231	Pancreatic perfusion was reduced in a patient with diabetes (0.60 ml min-1 ml-1) and in a failing pancreatic transplant (0.97 ml min-1 ml-1).
18	7788231	Values for perfusion in eight normal pancreases ranged between 1.25 and 1.66 ml min-1 ml-1 (mean: 1.52 ml min-1 ml-1).
19	7788231	Increased perfusion values were present in a patient with an islet cell tumour (overall perfusion 2.11 ml min-1 ml-1) and a patient with Wilson's disease (3.43 ml min-1 ml-1).
20	7788231	Pancreatic perfusion was reduced in a patient with diabetes (0.60 ml min-1 ml-1) and in a failing pancreatic transplant (0.97 ml min-1 ml-1).
21	8542744	Insulin-like growth factor-I and IGF-I receptors in diabetic patients with neuropathy.
22	8542744	Since a number of animal studies have shown that insulin-like growth I (IGF-I) stimulates nerve regeneration, the aim of our study was to evaluate the possible relationship between IGF-I and IGF-I receptors in diabetic patients with peripheral neuropathy.
23	8542744	The neuropathy study group had significantly lower levels of IGF-I:144.5 ng ml-1 (57.5-363.0, 95% confidence limits) compared to controls: 186.2 ng ml-1 (93.3-371.5), p < 0.01, and to diabetic patients without neuropathy: 173.7 ng ml-1 (83.1-363.0), p < 0.01.
24	8542744	In diabetic subjects there was a positive correlation (r = 0.20, p < 0.05) between IGF-I and HbA1, while in the neuropathy group there was a negative correlation between the score for nerve dysfunction with the IGF-I (r = -0.39, p < 0.01) and with IGF-I receptors (r = -0.34, p < 0.01).
25	12640021	Infusion with HiIL-6 and LoIL-6 resulted in a marked (P < 0.05) increase in systemic IL-6 concentration throughout the 3 h of infusion (mean arterial plasma [IL-6]s of 319 and 143 pg ml-1 for HiIL-6 and LoIL-6, respectively), followed by a rapid decline (P < 0.05) during the recovery period.
26	19127457	Recently, another linage of T cells has been described, namely T(H)17, characterized by production of IL-17, that differentiate in response to TGFbeta and IL-6 and participate in the pathogenesis of several autoimmune diseases.
27	19127457	Using RT-PCR analysis of gene expression, we analyzed the presence of T(H)1 (IL-12 and IFNgamma) and T(H)17 (TGFbeta, IL-6, IL-17A, IL-17F and IL-23) related cytokines in intestinal biopsies from CD patients with active disease compared to remission and from treated patients after acute, in vitro re-exposure to gliadin.
28	19380776	IL-23 drives pathogenic IL-17-producing CD8+ T cells.
29	19380776	IL-17-producing CD8(+) T cells (Tc17) appear to play a role in a range of conditions, such as autoimmunity and cancer.
30	19380776	We demonstrate that Tc17 and Th17 cells share similar developmental characteristics, including the previously unknown promoting effect of IL-21 on Tc17 cell differentiation and IL-23-dependent expression of IL-22.
31	19380776	Both STAT1 and STAT4 are required for optimal development of Tc17 cells and maximal secretion of cytokines.
32	19380776	Tc17 cells treated with TGF-beta1 plus IL-6 are not diabetogenic, whereas IL-23-treated cells potently induce the disease.
33	19380776	IL-17A and IL-17F are necessary but not sufficient for diabetes induction by Tc17 cells.
34	19380776	Tc17 cells treated with TGF-beta1 plus IL-6 or IL-23 likely differ in pathogenicity due to their disparate capacity to attract other immune cells and initiate inflammation.
35	20554001	IL-17A, IL-17F, IL-21, IL-22, IL-23, IL-6, TGF-beta) production in splenocytes was decreased dramatically on day 18 following CFA immunization.
36	20554001	IL-23 stimulation did not alter the distribution of IL-17 in myeloid cells.